Voxelotor is a Small Molecule owned by Pfizer, and is involved in 36 clinical trials, of which 22 were completed, 12 are ongoing, and 2 are planned. Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.

The revenue for Voxelotor is expected to reach a total of $6.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Voxelotor NPV Report.

Voxelotor was originated by University of California and is currently owned by Pfizer. Global Blood Therapeutics is the other company associated in development or marketing of Voxelotor.

Voxelotor Overview

Voxelotor (Oxbryta) is a hematologic agent. It is formulated as film coated tablets for oral route of administration. Voxelotor is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. Oxbryta is indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older, either as monotherapy or in combination with hydroxycarbamide.

Voxelotor (GBT-440) is under development for the treatment of sickle cell disease. The therapeutic candidate is administered through oral route. It acts by targeting hemoglobin. The drug candidate is developed based on Shape platform. The drug candidate was under development for the treatment of acute hypoxemic pulmonary fibrosis.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Voxelotor

Report Segments
  • Innovator (NME)
Drug Name
  • Voxelotor
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.